FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2144143416> ?p ?o ?g. }

• W2144143416 endingPage "713" @default.
• W2144143416 startingPage "713" @default.
• W2144143416 abstract "Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron Michelle Zhou, Marko Popovic, Mark Pasetka, Natalie Pulenzas, Soha Ahrari, Edward Chow, Carlo DeAngelis Department of Pharmacy, Odette Cancer Center, Sunnybrook Health Sciences Center, University of Toronto, Toronto, ON, Canada Purpose: Nausea and vomiting are major adverse effects of chemotherapy and can greatly impact patients’ quality of life. Although chemotherapy-induced nausea and vomiting (CINV) prevalence is high, treatment remains difficult. Palonosetron is a 5-hydroxytryptamine receptor antagonist (5-HT3RA) approved for treatment of CINV. The purpose of this review is to discuss existing and emerging therapeutic options, and examine studies focusing on palonosetron with regards to efficacy, pharmacology, tolerability, safety, and patient-derived outcomes.Methods: A literature search was conducted using Ovid MEDLINE and EMBASE to identify relevant studies using palonosetron alone or in combination with other antiemetics. Studies were extracted if they included complete response (CR), complete control (CC), no nausea, no vomiting, and no rescue medications as an endpoint. Studies were also included if safety endpoints were examined.Results: Palonosetron alone has been shown to improve CR and CC rates for patients receiving low, moderate, or high emetogenic chemotherapy. Rates were further improved with the addition of dexamethasone, a corticosteroid. Furthermore, the addition of neurokinin-1 receptor antagonists, such as netupitant markedly improved efficacy profiles compared to palonosetron alone. Aprepitant is an antiemetic that has exhibited positive results in combination with palonosetron. Recently, a new drug consisting of netupitant and palonosetron (NEPA) has demonstrated significantly more efficacious prevention of CINV. Regardless of the combination, palonosetron has been well tolerated. The most common adverse events were constipation, headache, fatigue, and dizziness, with the majority of patients describing them as only mild or moderate.Conclusion: Palonosetron, alone or with other antiemetics, has improved CINV treatment due to its ability to significantly reduce delayed phases of CINV, compared to similar 5-HT3RAs. Palonosetron is both more effective than first generation 5-HT3RAs and safer, as it results in a smaller prolongation of the QTc interval, compared to other 5-HT3RAs. Keywords: chemotherapy-induced nausea and vomiting, palonosetron, efficacy, safety, pharmacology, patient-reported outcomes" @default.
• W2144143416 created "2016-06-24" @default.
• W2144143416 creator A5001277262 @default.
• W2144143416 creator A5003945533 @default.
• W2144143416 creator A5034211616 @default.
• W2144143416 creator A5047114036 @default.
• W2144143416 creator A5052778717 @default.
• W2144143416 creator A5054523299 @default.
• W2144143416 creator A5077301363 @default.
• W2144143416 date "2015-05-01" @default.
• W2144143416 modified "2023-09-25" @default.
• W2144143416 title "Update on the management of chemotherapy-induced nausea and vomiting – focus on palonosetron" @default.
• W2144143416 cites W127899511 @default.
• W2144143416 cites W1502901901 @default.
• W2144143416 cites W1528154222 @default.
• W2144143416 cites W1963751388 @default.
• W2144143416 cites W1973339347 @default.
• W2144143416 cites W1978778773 @default.
• W2144143416 cites W1990573877 @default.
• W2144143416 cites W2003541101 @default.
• W2144143416 cites W2005339341 @default.
• W2144143416 cites W2005507717 @default.
• W2144143416 cites W2020302560 @default.
• W2144143416 cites W2020695269 @default.
• W2144143416 cites W2030225532 @default.
• W2144143416 cites W2030420314 @default.
• W2144143416 cites W2039300115 @default.
• W2144143416 cites W2048267573 @default.
• W2144143416 cites W2062133948 @default.
• W2144143416 cites W2066193518 @default.
• W2144143416 cites W2067359094 @default.
• W2144143416 cites W2083252039 @default.
• W2144143416 cites W2087393401 @default.
• W2144143416 cites W2091945071 @default.
• W2144143416 cites W2092980247 @default.
• W2144143416 cites W2100468927 @default.
• W2144143416 cites W2103776105 @default.
• W2144143416 cites W2113560537 @default.
• W2144143416 cites W2117833370 @default.
• W2144143416 cites W2120970263 @default.
• W2144143416 cites W2124217685 @default.
• W2144143416 cites W2126429670 @default.
• W2144143416 cites W2133609698 @default.
• W2144143416 cites W2133683152 @default.
• W2144143416 cites W2134823999 @default.
• W2144143416 cites W2149750503 @default.
• W2144143416 cites W2149837886 @default.
• W2144143416 cites W2150077308 @default.
• W2144143416 cites W2151039173 @default.
• W2144143416 cites W2155726820 @default.
• W2144143416 cites W2162984217 @default.
• W2144143416 cites W2164257257 @default.
• W2144143416 cites W2406133494 @default.
• W2144143416 cites W4253120901 @default.
• W2144143416 cites W1820860531 @default.
• W2144143416 doi "https://doi.org/10.2147/tcrm.s68130" @default.
• W2144143416 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4435088" @default.
• W2144143416 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25999723" @default.
• W2144143416 hasPublicationYear "2015" @default.
• W2144143416 type Work @default.
• W2144143416 sameAs 2144143416 @default.
• W2144143416 citedByCount "7" @default.
• W2144143416 countsByYear W21441434162015 @default.
• W2144143416 countsByYear W21441434162016 @default.
• W2144143416 countsByYear W21441434162017 @default.
• W2144143416 crossrefType "journal-article" @default.
• W2144143416 hasAuthorship W2144143416A5001277262 @default.
• W2144143416 hasAuthorship W2144143416A5003945533 @default.
• W2144143416 hasAuthorship W2144143416A5034211616 @default.
• W2144143416 hasAuthorship W2144143416A5047114036 @default.
• W2144143416 hasAuthorship W2144143416A5052778717 @default.
• W2144143416 hasAuthorship W2144143416A5054523299 @default.
• W2144143416 hasAuthorship W2144143416A5077301363 @default.
• W2144143416 hasBestOaLocation W21441434161 @default.
• W2144143416 hasConcept C126322002 @default.
• W2144143416 hasConcept C143998085 @default.
• W2144143416 hasConcept C197934379 @default.
• W2144143416 hasConcept C2776712918 @default.
• W2144143416 hasConcept C2778375690 @default.
• W2144143416 hasConcept C2779924295 @default.
• W2144143416 hasConcept C2780574406 @default.
• W2144143416 hasConcept C2780580376 @default.
• W2144143416 hasConcept C2780852908 @default.
• W2144143416 hasConcept C2780884295 @default.
• W2144143416 hasConcept C42219234 @default.
• W2144143416 hasConcept C71924100 @default.
• W2144143416 hasConcept C98274493 @default.
• W2144143416 hasConceptScore W2144143416C126322002 @default.
• W2144143416 hasConceptScore W2144143416C143998085 @default.
• W2144143416 hasConceptScore W2144143416C197934379 @default.
• W2144143416 hasConceptScore W2144143416C2776712918 @default.
• W2144143416 hasConceptScore W2144143416C2778375690 @default.
• W2144143416 hasConceptScore W2144143416C2779924295 @default.
• W2144143416 hasConceptScore W2144143416C2780574406 @default.
• W2144143416 hasConceptScore W2144143416C2780580376 @default.
• W2144143416 hasConceptScore W2144143416C2780852908 @default.
• W2144143416 hasConceptScore W2144143416C2780884295 @default.
• W2144143416 hasConceptScore W2144143416C42219234 @default.

• next